Survival Outcomes and Patterns of Recurrence in Patients with Stage III or IV Oropharyngeal Cancer Treated with Primary Surgery or Radiotherapy

Purpose To compare and contrast the patterns of failure in patients with locally advanced squamous cell oropharyngeal cancers undergoing curative-intent treatment with primary surgery or radiotherapy +/- chemotherapy. Methods and materials Two hundred and thirty-three patients with stage III or IV oropharyngeal squamous cell carcinoma who underwent curative-intent treatment from 2006-2012, were reviewed. The median length of follow-up for patients still alive at the time of analysis was 4.4 years. Data was collected retrospectively from a chart review. Results One hundred and thirty-nine patients underwent primary surgery +/- adjuvant therapy, and 94 patients underwent primary radiotherapy +/- chemotherapy (CRT). Demographics were similar between the two groups, except primary radiotherapy patients had a higher age-adjusted Charleston co-morbidity score (CCI). Twenty-nine patients from the surgery group recurred; 15 failed distantly only, seven failed locoregionally, and seven failed both distantly and locoregionally. Twelve patients recurred who underwent chemoradiotherapy; ten distantly alone, and two locoregionally. One patient who underwent radiotherapy (RT) alone failed distantly. Two and five-year recurrence-free survival rates for patients undergoing primary RT were 86.6% and 84.9% respectively. Two and five-year recurrence-free survival rates for primary surgery was 80.9% and 76.3% respectively (p=0.21). There was no significant difference in either treatment when they were stratified by p16 status or smoking status. Conclusions Our analysis does not show any difference in outcomes for patients treated with primary surgery or radiotherapy. Although the primary pattern of failure in both groups was distant metastatic disease, some local failures may be preventable with careful delineation of target volumes, especially near the base of skull region.

[1]  A. Garden,et al.  A multi‐institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensity‐modulated radiotherapy , 2015, Cancer.

[2]  Sue S Yom,et al.  Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Ang,et al.  Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Higgins,et al.  Management of oropharyngeal cancer: a cross-sectional review of institutional practice at a large Canadian referral centre , 2014, Journal of Otolaryngology - Head & Neck Surgery.

[5]  J. Waldron,et al.  Comorbidity and prognosis in head and neck cancers: Differences by subsite, stage, and human papillomavirus status , 2014, Head & neck.

[6]  D. O’Connell,et al.  Primary surgery versus chemoradiotherapy for advanced oropharyngeal cancers: a longitudinal population study , 2013, Journal of Otolaryngology - Head & Neck Surgery.

[7]  Suzanne L Wolden,et al.  Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience. , 2012, International journal of radiation oncology, biology, physics.

[8]  M. Zelefsky,et al.  Long-term Regional Control in the Observed Neck following Definitive Chemoradiation for Node-positive Oropharyngeal Squamous Cell Cancer , 2011 .

[9]  M. Kaplan,et al.  Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: clinical outcomes and patterns of failure. , 2010, International journal of radiation oncology, biology, physics.

[10]  Walter R. Bosch,et al.  Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). , 2010, International journal of radiation oncology, biology, physics.

[11]  P. Xia,et al.  Intensity‐modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma , 2008, Cancer.

[12]  M. van Glabbeke,et al.  Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501) , 2005, Head & neck.

[13]  J. Cooper,et al.  Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence? , 2005, The oncologist.

[14]  L. Dawson,et al.  Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. , 2004, International journal of radiation oncology, biology, physics.